Kura Oncology, Inc. (KURA) vs Seaport Therapeutics, Inc. Common Stock (SPTX)

A side-by-side comparison of Kura Oncology, Inc. and Seaport Therapeutics, Inc. Common Stock across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Kura Oncology, Inc. logo
KURA
Kura Oncology, Inc.
$939M
$10.57HealthcareDelayed quote: Oct 6, 2026, 3:00 PM EDT
Seaport Therapeutics, Inc. Common Stock logo
SPTX
Seaport Therapeutics, Inc. Common Stock
$930M
$17.38HealthcareDelayed quote: Oct 6, 2026, 2:55 PM EDT

Total return — KURA vs SPTX

growth of $100 · dividends reinvested · last 1y
KURA +20.3% (+20.3%/yr)SPTX -6.8% (-6.8%/yr)KURA compounded faster over this window
80100120140Start $100$120$93
KURA SPTX

KURA vs SPTX: by the numbers

  • •KURA is the larger company ($939M vs $930M market cap).
  • •Both run net losses; SPTX's is the smaller (0.00% vs -384.30% net margin).

Metrics side by side

Valuation

MetricKURASPTX
P/S ratio12.15N/A
P/B ratio19.382.20

Profitability

MetricKURASPTX
Gross margin94.73%0.00%
Operating margin-449.94%0.00%
Net margin-384.30%0.00%
ROE-612.78%N/A
ROIC-67.13%-36.95%

Growth (annualized)

MetricKURASPTX
Total return CAGR (5Y)-10.73%N/A

Go deeper

Full KURA analysisFull SPTX analysisInteractive comparison tool

Dig into the metrics

Kura Oncology ROESeaport Therapeutics, Inc. Common Stock ROEKura Oncology operating marginSeaport Therapeutics, Inc. Common Stock operating marginKura Oncology revenue growthSeaport Therapeutics, Inc. Common Stock revenue growthKura Oncology free cash flowSeaport Therapeutics, Inc. Common Stock free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.